|
Resistance rates in S. aureus isolates from human colonization
| | | | |
|
Penicillin(420)
|
(96–100)
|
(416/420)
|
(99%)
|
Joachim et al. (2018), Geofrey et al. (2015), Joachim et al. (2017), Moremi et al. (2019)
|
|
Ampicillin (151)
|
(84–100)
|
(133/151)
|
(88%)
|
Katakweba et al. (2016), Okamo et al. (2016), Ngocho et al. (2015)
|
|
Tetracycline (381)
|
(9–95)
|
(103/381)
|
(27%)
|
Geofrey et al. (2015), Moyo et al. (2014), Katakweba et al. (2016), Okamo et al. (2016), Moremi et al. (2019)
|
|
Erythromycin (402)
|
(19–100)
|
(163/402)
|
(41%)
|
Joachim et al. (2018), Geofrey et al. (2015), Okamo et al. (2016), Moremi et al. (2019)
|
|
Gentamicin (540)
|
(9–34)
|
(105/540)
|
(21%)
|
Joachim et al. (2018), Joachim et al. (2017), Moyo et al. (2014), Katakweba et al. (2016), Moremi et al. (2019), Ngocho et al. (2015)
|
|
Co-trimoxazole (443)
|
(14–66)
|
(205/443)
|
(46%)
|
Joachim et al. (2018), Geofrey et al. (2015), Moyo et al. (2014), Katakweba et al. (2016), Moremi et al. (2019)
|
|
Ciprofloxacin (233)
|
(4–11)
|
(15/233)
|
(6%)
|
Joachim et al. (2017), Moyo et al. (2014)
|
|
Clindamycin (336)
|
(9–76)
|
(33/336)
|
(9.8%)
|
Joachim et al. (2018), Geofrey et al. (2015), Moremi et al. (2019)
|
|
Cefoxitin (546)
|
(2–100)
|
(103/546)
|
(19%)
|
Joachim et al. (2018, Geofrey et al. (2015), Moyo et al. (2014), Okamo et al. (2016), Moremi et al. (2019)
|
|
Resistance rates in S. aureus isolates from invasive (blood-borne) infections
| | | | |
|
Penicillin (46)
|
(23–80)
|
(40/46)
|
(87%)
|
Kayange et al. (2010), Onken et al. (2015), Thriemer et al. (2012)
|
|
Ampicillin (50)
|
(85–100)
|
(46/50)
|
(92%)
|
Mhada et al. (2012, Seni et al. (2019a)
|
|
Erythromycin (60)
|
(20–66)
|
(38/60)
|
(63%)
|
Kayange et al. (2010), Seni et al. (2019a, Thriemer et al. (2012)
|
|
Gentamicin (50)
|
(26–56)
|
(21/50)
|
(42%)
|
Mhada et al. (2012), Seni et al. (2019a)
|
|
Co-trimoxazole (69)
|
(22–96)
|
(46/69)
|
(66%)
|
Kayange et al. (2010), Seni et al. (2019a), Onken et al. (2015), Thriemer et al. (2012)
|
|
Clindamycin (32)
|
(44)
|
(14/32)
|
(44%)
|
Kayange et al. (2010)
|
|
Methicillin (245)
|
(23)
|
(57/245)
|
(23%)
|
Moyo et al. (2010)
|
|
Cefoxitin (69)
|
(0–32)
|
(17/69)
|
(25%)
|
Kayange et al. (2010; Seni et al. (2019a), Onken et al. (2015), Thriemer et al. (2012)
|
|
Resistance rates in S. aureus isolates from non-invasive infections
| | | | |
|
Penicillin (202)
|
(30–100)
|
(183/202)
|
(91%)
|
Manyahi et al. (2014), Kazimoto et al. (2018), Moremi et al. (2014), Marwa et al. (2015), Moremi et al. (2012)
|
|
Ampicillin (263)
|
(47–88)
|
(177/263)
|
(67%)
|
Mhada et al. (2012), Mwambete and Eulambius (2018)
|
|
Tetracycline (67)
|
(6–45)
|
(14/67)
|
(21%)
|
Marwa et al. (2015), Mushi et al. (2016), Moremi et al. (2012)
|
|
Erythromycin (221)
|
(14–46)
|
(81/221)
|
(37%)
|
Moremi et al. (2014), Marwa et al. (2015), Mushi et al. (2016), Moremi et al. (2012)
|
|
Gentamicin (339)
|
(11–52)
|
(110/339)
|
(32%)
|
Mhada et al. (2012), Mwambete and Eulambius (2018), Moremi et al. (2014), Mushi et al. (2016), Moremi et al. (2012)
|
|
Co-trimoxazole (232)
|
(43–74)
|
(115/232)
|
(50%)
|
Mwambete and Eulambius (2018), Moremi et al. (2014), Marwa et al. (2015), Mushi et al. (2016) Seni et al. (2019b), Moremi et al. (2012)
|
|
Ciprofloxacin (187)
|
(4–25)
|
(20/187)
|
(17%)
|
Mwambete and Eulambius (2018), Marwa et al. (2015), Mushi et al. (2016)
|
|
Clindamycin (42)
|
(21–63)
|
(19 /42)
|
(45%)
|
Moremi et al. (2014), Moremi et al. (2012)
|
|
Cefoxitin (226)
|
(1–100)
|
(55/226)
|
(24%)
|
Manyahi et al. (2014), Kazimoto et al. (2018), Moremi et al. (2014), Mushi et al. (2016), Moremi et al. (2012)
|
